Valneva Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Valneva non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-18.7%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-18.7%
Rendimento futuro dei dividendi	0.5%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di VALN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di VALN siano aumentati.

Rendimento dei dividendi rispetto al mercato

Valneva Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di VALN rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (VALN)	n/a
Fondo del 25% del mercato (US)	1.3%
Top 25% del mercato (US)	4.2%
Media del settore (Biotechs)	2.3%
Analista previsionale (VALN) (fino a 3 anni)	0.5%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di VALN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di VALN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di VALN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché VALN non ha segnalato alcun pagamento.

Valneva Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Valneva seeking a partnership for next-gen COVID-19 vaccine

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva shows booster effect of COVID shot against AstraZeneca vaccine

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Valneva launches up to $75M at-the-market ADS offering program

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love

Valneva agrees to cut COVID vaccine supplies to EU

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti